Produktname:2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine

IUPAC Name:2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine

CAS:90213-66-4
Molekulare Formel:C6H3Cl2N3
Reinheit:98%
Katalognummer:CM103618
Molekulargewicht:188.01

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM103618-100g in stock ȋş
CM103618-500g in stock ƏƏŭ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:90213-66-4
Molekulare Formel:C6H3Cl2N3
Schmelzpunkt:-
SMILES-Code:ClC1=NC(Cl)=C2C=CNC2=N1
Dichte:
Katalognummer:CM103618
Molekulargewicht:188.01
Siedepunkt:
Mdl-Nr.:MFCD08059278
Lagerung:-20°C

Category Infos

Pyrrolopyrimidines
Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.

Column Infos

Capivasertib
On November 16, FDA approved Capivasertib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative locally advanced or metastatic breast cancer. Capivasertib is a highly selective inhibitor targeting three AKT subtypes (AKT1/2/3), which can block signals used by cancer cells for division and growth.